Fujian Huisheng Biotech Files IPO Prospectus Highlighting Two Globally Unique Marine Microbial Strains and Nearly 40 Commercialized Products

In 1961, Soviet cosmonaut Yuri Gagarin became the first human to journey into outer space. The spacecraft carried him to an orbit 320 kilometers above Earth, and he returned after completing one revolution around the planet. “Although the sky was extremely dark, the Earth appeared blue and remarkably clear,” he described our planet as a “blue celestial body,” given that 71% of its surface is covered by oceans.

The vast and boundless ocean world is both mysterious and vibrant, with its 360 million square kilometers harboring abundant biological resources. It is estimated that marine ecosystems contain between 200 million and 1 billion species, exhibiting ecological community structural diversity and species diversity unparalleled by terrestrial microorganisms.

Among these, marine microbial resources are vast in quantity; the microbial biomass in the deep-sea floor alone accounts for 56% of the Earth’s total biomass. Marine microorganisms possess significant scientific and resource value, serving as a crucial source of raw materials widely applied in fields such as food, biopharmaceuticals, and agriculture. As an important national strategic resource, marine microbial resources constitute a key technological asset for future advancements in biotechnology, life sciences research, and industrial innovation.

Among them, Fujian Huisheng Biotechnology Co., Ltd. (hereinafter referred to as “Fujian Huisheng Biotech”) is a high-tech enterprise dedicated to exploring marine microbial strains and developing the marine economy. Established in 2016, the company has been recognized as a National High-Tech Enterprise, a Fujian Province Technology-Based Small and Medium-sized Enterprise, a Fujian Province Innovative Small and Medium-sized Enterprise, and a New Type R&D Institution in Zhangzhou City.

Fujian Huisheng Biotechnology is dedicated to the research, development, production, and application of bioactive substances derived from marine microbial strains. The company has established a comprehensive management system covering the entire value chain, from raw material extraction, purification, synthesis, and preparation to manufacturing and sales.The company's main products include enzyme preparations, animal health microecological preparations, probiotics, and oligosaccharides, with a wide range of applications. Fujian Huisheng Biology has independently developed multiple innovative technologies,Possesses the world’s only *Lactobacillus plantarum* strain derived from deep-sea beaked whales and a strain capable of efficiently synthesizing alginate oligosaccharides through fermentation, with established corresponding processes.Meanwhile, the company is a strategic private-sector partner of the Third Institute of Oceanography, Ministry of Natural Resources, and a supplier of biological enzyme preparations to Fujian Tobacco.

Huang Qinmiao, Founder of Fujian Huisheng BiotechWith nearly a decade of dedication to the research and industrial application of marine microecology, he serves as an Executive Director of the Fujian Marine Society and holds a certificate from the APEC Center for Technology Exchange and Training for Ocean Sustainable Development. He is the primary inventor of two invention patents, one software copyright, and 22 utility model patents. Furthermore, Huang Qinmiao has led collaborative projects with the Chinese Academy of Sciences (CAS) for the commercialization of scientific and technological achievements, as well as multiple patent transformation projects with the Third Institute of Oceanography, Ministry of Natural Resources. He has also published a research paper on “Lactobacillus plantarum HJ-S2” in the World Journal of Microbiology and Biotechnology.

When discussing the origins of his entrepreneurial journey, Huang Qinmiao stated that it stemmed from his vision to contribute to the development of China’s own independent brands. During the few years after completing his studies and entering the workforce, he keenly perceived the shortcomings in China’s construction of independent brands at the time. “Especially in the fields of biotechnology and biological products, developed countries such as the United States were approximately ten to twenty years ahead of us.” Recognizing both the immense potential of biotechnology to benefit public health and the challenges posed by domestic developmental gaps in this sector, Huang Qinmiao established biotechnology as his primary focus for entrepreneurship.

In 2016, Fujian Huisheng Biotechnology was established in Zhangzhou, Fujian Province, formally entering the microbial preparation industry with a focus on the development and industrialization of marine microbial strains. When discussing the reasons for the company’s primary focus on the development, engineering, and application of marine microorganisms, Huang Qinmiao stated that, on one hand, globally, the development of marine resources is relatively underdeveloped compared to terrestrial sources, leaving considerable room for exploration. On the other hand, as the cradle of primordial life, the ocean has existed for billions of years; its ancient history and more primitive environment make it more likely to break through the current technological constraints in resource development and achieve qualitative leaps.

In 2018, the Company established a collaborative partnership with the Third Institute of Oceanography, Ministry of Natural Resources, jointly founding the “Joint R&D Center for Marine Biological Products” and becoming its strategic private-sector partner.The Marine Culture Collection of China (MCCC) at the Third Institute of Oceanography has now become the world’s largest marine microbial culture collection center,FujianHuisheng Bio holds the priority right to commercialize the marine microbiology research achievements of the Third Institute of Oceanography.From 2018 to 2021, the company successively collaborated with the Third Institute of Oceanography, Fujian China Tobacco, Huaqiao University, and other partners on more than ten projects involving provincial ministries, state-owned enterprises, university-enterprise partnerships, and research institutes, achieving a series of significant scientific research outcomes and corporate honors.

Fujian Huisheng Biology and the Third Institute of Oceanography Jointly Establish a Joint R&D Center

Currently, the company has established two business pipelines: fermentation expression and synthetic biology laboratories. These pipelines cover four product series: animal health, enzyme preparations, human health, and oligosaccharides. The overall development strategy follows a progression from easy to difficult tasks and from macromolecules to small molecules.

Currently, the vast majority of probiotics available on the domestic market are derived from terrestrial sources, while marine-derived probiotics remain relatively scarce. “Strains isolated from marine environments are generally older than their terrestrial counterparts; their genes have existed for longer periods and exhibit greater stability. Although development poses greater challenges, it also offers opportunities for unprecedented breakthroughs,” Huang Qinmiao explained to VCBeat.

Moreover, the majority of probiotic products offered by domestic enterprises are licensed from foreign companies, with Chinese firms merely engaged in contract manufacturing. The entire probiotic market is monopolized by leading overseas enterprises, which account for approximately 80%–90% of the market share. “This raises a serious concern. China lacks proprietary strains with independent intellectual property rights. Should trade frictions arise and lead to controls on strains and pharmaceuticals, it would directly impede the development and application of related microbial preparations in China.” Meanwhile, Huang Qinmiao pointed out that experimental subjects in foreign strain development processes are generally non-Chinese individuals. Given the genetic differences between these populations and ethnic Chinese, the experimental results exhibit a certain degree of exclusivity and may not be highly compatible with the physiological characteristics of the Chinese population.

Therefore,FujianHuisheng Biotech has been committed to developing core bacterial strains with independent intellectual property rights, achieving “mastery of strains from the source.”. Currently,FujianHuisheng Bio has established a complete industrial chain spanning from strain screening and isolation to development, engineering, and large-scale production. According to Huang Qinmiao, this is a rarity among other enterprises in China.“This enables us to gain a deeper understanding of the characteristics and functional targets of these strains, perform targeted environmental adaptation, and thereby enhance their biological stability.”

Headquarters of Fujian Huisheng Bio-Intelligent Manufacturing Industrial Park

Currently,FujianHuisheng Bio has developed two core strains that are currently “globally unique.” These core strains possess specific efficacies distinct from most strains available on the market, have secured a series of patent protections, and have been the subject of multiple research papers published in international journals.。

Among them,The HJ-S2 core strain is currently the only *Lactobacillus plantarum* worldwide derived from deep-sea beaked whales. This lactic acid bacterium, screened and isolated from the viscera of beaked whales by Fujian Huisheng Biotechnology, exhibits high-efficiency cholesterol-lowering capabilities.The cholesterol-lowering capacity of Lactobacillus HJ-S2 in vitro reached 48.82%. Its survival rate was 82.73% after 3 hours of incubation in an acidic environment at pH 3, and 80.62% after 3 hours in an environment containing 0.3% bile salts. The metabolites of this strain exhibited certain inhibitory effects against the pathogenic bacteria Escherichia coli, Staphylococcus aureus, and Salmonella. Furthermore, the strain demonstrated strong adhesion to human colon cancer cells HT-29, with an adhesion count of 132.52.

Additionally,FujianHuisheng Bio has developed the world’s only microbial strain capable of efficiently synthesizing alginate oligosaccharides through fermentation and established the corresponding production process.Alginate oligosaccharides are functional oligosaccharides derived from alginate through specific cleavage reactions. They exhibit good solubility, strong stability, and high biological activity, with demonstrated effects including anti-tumor, anti-inflammatory, immunomodulatory, and lipid-lowering properties. “Under normal circumstances, most sugars consumed by the human body are complex carbohydrates, which require two to three rounds of breakdown and digestion before absorption, resulting in low utilization efficiency. In contrast, the advantage of oligosaccharides lies in their ease of absorption; essentially, the amount supplemented is nearly fully absorbed,” explained Huang Qinmiao.

Traditional methods for preparing alginate oligosaccharides involve the enzymatic degradation of large brown algae. On one hand, this process is cumbersome and prone to causing environmental pollution. Furthermore, the degree of polymerization of alginate oligosaccharides produced via enzymatic hydrolysis is unstable, which may lead to inconsistent efficacy. On the other hand, China generally relies on imports for large-scale algae, resulting in high raw material, tariff, and logistics costs, as well as limited supply chain stability.

andFujianHuisheng Biotech’s fucoidan oligosaccharide products leverage proprietary microbial strains and synthetic biology technologies and processes, eliminating the need to procure brown algae raw materials by enabling direct oligosaccharide production from the strains. This approach reduces preparation steps and processes, minimizes contamination risks, lowers costs, and enhances production efficiency.According to Huang Qinmiao, empowered by this proprietary technology, Fujian Huisheng Biotechnology can significantly reduce production costs compared to existing oligosaccharide preparation methods on the market. Currently, the company’s oligosaccharide products are in the stage of backend process scale-up and efficacy validation, holding broad application prospects in the fields of pharmaceuticals, health supplements, cosmetics, animal feed, and plant regulators.

Fujian Huisheng Biotech’s deep-sea probiotic products undergo whole-genome sequencing and are screened from over 100,000 biological samples and 26,000 microbial strains. They utilize patented core strains sourced from the deep sea, which offer benefits such as cholesterol reduction and selenium enrichment. Combined with prebiotic and postbiotic components, each tube contains 30 billion CFU of active probiotics. The product employs advanced ultra-low-temperature vacuum freeze-drying technology and is specially packaged in aluminum foil with nitrogen flushing to preserve viability. This ensures that while consumers supplement with probiotics, the proliferation and colonization of beneficial bacteria are promoted, achieving a tripartite effect of “supplementation + nourishment + protection.” Meanwhile,The strains used are protected by proprietary intellectual property rights, and the production chain is independently controlled, resulting in significant cost advantages.The company’s currently marketed probiotic products include seven formulations: Selenium-Enriched Probiotics, Tangyan Probiotics, Gut Probiotics, Men’s Probiotics, Women’s Probiotics, Sleep Probiotics, and Shufeng Probiotics.

Fujian Huisheng Biotechnology Deep-Sea Probiotic Products

According to Fujian Huisheng Biology, search results across major e-commerce platforms show thatThe Company’s currently marketed probiotic products possess functionalities rarely seen among comparable competitors, conferring a differentiated advantage in terms of product efficacy.

This is primarily attributed to the extensive and diverse applications of the product’s core strain, *Lactiplantibacillus plantarum* HJ-S2. This strain reduces cholesterol synthesis through the interaction of its metabolites with reductases. It also produces bioactive molecules that help regulate insulin sensitivity, influence glucose metabolism, and inhibit hepatic glucose production, thereby lowering blood glucose levels. Furthermore, when combined with *Bifidobacterium animalis* subsp. *lactis*, *L. plantarum* HJ-S2 can directly inhibit the growth and proliferation of harmful bacteria and lower intestinal pH, thus reducing the risk of intestinal infections. In combination with *Lacticaseibacillus rhamnosus*, it produces antimicrobial substances (such as lactic acid and bacteriocins) to maintain vaginal microecological balance. Additionally, selenium-enriched *L. plantarum* HJ-S2 can modulate levels of GABA and 5-hydroxytryptamine (serotonin), regulate autonomic nervous system function, and improve sleep quality. It also promotes normal sperm development and function by providing nutrients and regulating environmental conditions.

The company’s probiotic products are currently produced and sold through a hybrid model of “proprietary brands plus external partnerships.” On one hand, it leverages its core star strains to build consumer-facing (C-end) proprietary brands. On the other hand, in business-to-business (B-end) supply chain services, it establishes collaborations with large enterprises by providing contract manufacturing services or supplying its proprietary strains as starter cultures for other probiotic brands. In addition, Fujian Huisheng Biotechnology will adopt complementary partnership models to jointly co-create new brands with its partners.

In the animal health sector, Fujian Huisheng Biotechnology’s microbial ecological products are developed based on research into marine microbial strains. Free from any chemical additives, these products enhance disease resistance in aquaculture, improve water quality, and inhibit the growth of harmful bacteria. The current product portfolio includes multiple series: water quality regulation, intestinal protection, water fertilization and bottom modification, detoxification and anti-stress, liver protection and care, and growth promotion.More than 30 products have been launched.

Fujian Huisheng Biological Animal Health Microecological Preparations

As a national-level high-tech enterprise, Fujian Huisheng Biology holds 46 patents, including 11 invention patents, 35 utility model patents, and one computer software copyright. Additionally, three invention patent applications have been filed and are currently under examination. Meanwhile, the company has established unique technological process advantages through non-patent approaches, such as constructing in-house GMP-compliant production lines, customizing non-standard equipment, and optimizing process parameters.

Looking ahead, Fujian Huisheng Bio will continue to deepen its engagement in its current two business pipelines and four product segments through R&D innovation. Leveraging the advanced scientific achievements of the Third Institute of Oceanography, Ministry of Natural Resources, the company remains committed to making high-value development of marine microorganisms its long-term strategic focus. By establishing a “one core, multiple wings” rapid development framework, Fujian Huisheng Bio aims to contribute new momentum to the exploitation of marine microbial resources and the growth of the big health industry.